347 results on '"Borghaei, Hossein"'
Search Results
2. Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
3. Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study
4. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
5. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
6. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
7. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)
8. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
9. Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management
10. How to Treat EGFR-Mutated Non–Small Cell Lung Cancer
11. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
12. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
13. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
14. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
15. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
16. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
17. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
18. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901
19. A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
20. Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
21. Combining Immunotherapy and Chemotherapy for Non–Small Cell Lung Cancer
22. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
23. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
24. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib
25. Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11 -Mutant Non–Small-Cell Lung Cancer.
26. Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
27. Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non–Small Cell Lung Cancer
28. Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer
29. Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma
30. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
31. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
32. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
33. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
34. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
35. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non–Small-Cell Lung Cancer
36. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis
37. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer
38. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
39. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
40. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
41. ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
42. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma
43. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227.
44. ISY8-2 - Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer
45. Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort
46. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
47. Nivolumab in Nonsquamous Non–Small-Cell Lung Cancer
48. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
49. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
50. Immunotherapy of cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.